HHS-OIG Identifies Potential Misuse of HRAs and Chart Reviews by MA Companies
The Department of Health and Human Services Office of Inspector General (HHS-OIG) has identified potential misuse of health risk assessments (HRAs) and HRA-linked chart reviews by Medicare Advantage (MA) companies, which may have resulted in millions of dollars in overpayments.
The Centers for Medicare and Medicaid Services (CMS) pays MA companies higher risk-adjusted payments for sicker enrollees to cover costlier care and each year, MA companies receive millions in overpayments based on unsupported diagnoses for MA enrollees. When diagnoses are reported only using enrollees’ HRAs and HRA-linked chart reviews and there are no follow-up visits, procedures, or tests, HHS-OIG is concerned that the diagnoses may be inaccurate and therefore the payments made by the CMS may be improper. Alternatively, the lack of follow-up visits and tests suggests that if the diagnoses are accurate, enrollees have not received the necessary care for serious health conditions.
HHS-OIG’s analysis of MA encounter data identified 1.7 million MA enrollees whose diagnoses were only reported using HRAs and HRA-linked chart reviews and did not include any follow-ups. Out of the 17 million MA enrollees, 19,028 enrollees had no other service records at all in 2022 apart from a single HRA. HHS-OIG estimates that around $7.5 billion in MA risk-adjusted payments were made for 2023 and that 80% of those payments were made to just 20 MA companies.
Almost two-thirds of those payments were based only on In-home HRAs and HRA-linked chart reviews, which have a higher risk of misuse as they are usually administered by MA companies and their third-party vendors rather than enrollees’ own providers. In fiscal year 2023, the CMS identified $12.7 billion in net overpayments due to plan-submitted diagnoses that were not supported by documentation in enrollees’ medical records and concerns have been raised by oversight entities that MA companies are using HRA and HRA-type assessments to maximize their risk-adjusted payments rather than to improve the care provided to enrollees. HHS-OIG says the risk-adjustment payment policy creates a financial incentive for MA companies to misrepresent health statuses and submit unsupported diagnoses to inflate their risk-adjusted payments.
HHS OIG Exclusions List
What You Need To Know
Get The 6 Essentials Checklist For Compliance Officers
A link to your download will be sent to your email address
Your Privacy Respected
HIPAA Journal Privacy Policy
HHS-OIG recommended the CMS take steps to identify and prevent misuse of HRAs and HRA-linked chart reviews. HHS-OIG suggested the CMS impose additional restrictions on the use of diagnoses reported only on in-home HRAs or chart reviews linked to in-home HRAs for risk-adjusted payments, conduct audits to validate diagnoses reported using only HRAs and HRA-linked chart reviews, and determine whether certain health conditions such as diabetes and congestive heart failure that drove payments on in-home HRAs and chart reviews are more vulnerable to misuse by MA companies. The CMS only concurred with the last recommendation.
